Orenburg Regional Clinical Oncology Center

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Michael Friedländer, Ursula A. Matulonis, Charlie Gourley et al. · British Journal of Cancer · 2018 · 177 citations · Full text

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Rebecca Kristeleit, Vadim Shirinkin, Fatima El-Khouly et al. · Gynecologic Oncology · 2017 · 100 citations

Medicine, Gynecology, Pathology +9

FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Salah‐Eddin Al‐Batran, Martin Schüler, Zanete Zvirbule et al. · Journal of Clinical Oncology · 2016 · 46 citations

Esophageal Cancer, Lba4001 Background, Immunology +22

Different types of tumor vessels in breast cancer: morphology and clinical value

M. A. Senchukova, Olesia N. Tomchuk, Nikon V. Zaitsev et al. · SpringerPlus · 2015 · 41 citations · Full text

Tumor Vessels, Breast Oncology, Pathology +16

Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

Charlie Gourley, Michael Friedländer, Ursula A. Matulonis et al. · Journal of Clinical Oncology · 2017 · 24 citations

Olaparib Tolerability Profile, Cancer Management, Gynecology +16